The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 18, 2014

Filed:

Jun. 05, 2002
Applicants:

Steven A. Fischkoff, Short Hills, NJ (US);

Joachim Kempeni, Neustadt, DE;

Roberta Weiss, Wynnewood, PA (US);

Inventors:

Steven A. Fischkoff, Short Hills, NJ (US);

Joachim Kempeni, Neustadt, DE;

Roberta Weiss, Wynnewood, PA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/241 (2013.01); A61K 39/3955 (2013.01); C07K 2317/76 (2013.01); A61K 2300/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); A61K 2039/54 (2013.01); C07K 2317/21 (2013.01);
Abstract

Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.


Find Patent Forward Citations

Loading…